Studies have shown promise in treating Alzheimer’s and Parkinson’s with GLP-1 drugs, perhaps by regulating insulin levels and reducing inflammation, and the drugs may yet prove useful in treating many other conditions made worse by chronic inflammation. Some studies have found large decreases in the risk of depression and anxiety; others found... See more

The Canadian scientist Daniel Drucker, who has done more than practically anyone in the world to illuminate the benefits of GLP-1 drugs, proposed that GLP-1’s anti-inflammatory effects could provide a “unifying” mechanism for these drugs’ effectiveness:

But excessive chronic inflammation, which results from an immune system over-policing threats throughout the body, is a leading cause of organ damage, stroke, and neurological problems. GLP-1 drugs seem to bind to receptors throughout the body—in our gut, on our immune cells, and throughout the central nervous system—to broadcast the same message:... See more